- Home
- DOX vs EXAS Comparison
DOX vs EXAS Comparison
Compare DOX & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOX
- EXAS
- Stock Information
- Founded
- DOX 1982
- EXAS 1995
- Country
- DOX United States
- EXAS United States
- Employees
- DOX N/A
- EXAS N/A
- Industry
- DOX EDP Services
- EXAS Medical Specialities
- Sector
- DOX Technology
- EXAS Health Care
- Exchange
- DOX Nasdaq
- EXAS Nasdaq
- Market Cap
- DOX 10.2B
- EXAS 10.5B
- IPO Year
- DOX 1998
- EXAS N/A
- Fundamental
- Price
- DOX $85.70
- EXAS $54.26
- Analyst Decision
- DOX Strong Buy
- EXAS Strong Buy
- Analyst Count
- DOX 5
- EXAS 16
- Target Price
- DOX $101.20
- EXAS $72.80
- AVG Volume (30 Days)
- DOX 595.7K
- EXAS 2.2M
- Earning Date
- DOX 02-04-2025
- EXAS 02-19-2025
- Dividend Yield
- DOX 2.24%
- EXAS N/A
- EPS Growth
- DOX N/A
- EXAS N/A
- EPS
- DOX 4.25
- EXAS N/A
- Revenue
- DOX $5,004,989,000.00
- EXAS $2,692,328,000.00
- Revenue This Year
- DOX N/A
- EXAS $11.81
- Revenue Next Year
- DOX $4.75
- EXAS $11.52
- P/E Ratio
- DOX $19.99
- EXAS N/A
- Revenue Growth
- DOX 2.40
- EXAS 11.91
- 52 Week Low
- DOX $74.41
- EXAS $40.62
- 52 Week High
- DOX $94.04
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- DOX 52.84
- EXAS 43.56
- Support Level
- DOX $81.75
- EXAS $49.79
- Resistance Level
- DOX $85.50
- EXAS $60.88
- Average True Range (ATR)
- DOX 1.26
- EXAS 2.78
- MACD
- DOX 0.18
- EXAS -0.42
- Stochastic Oscillator
- DOX 86.43
- EXAS 40.31
About DOX Amdocs Limited
Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.